Ronald Blanck Net Worth

The estimated Net Worth of Ronald R Blanck is at least $27.4 Mille dollars as of 18 May 2020. Ronald Blanck owns over 5,000 units of Tenax Therapeutics Inc stock worth over $22,308 and over the last 10 years he sold TENX stock worth over $5,051. In addition, he makes $0 as Independent Chairman of the Board at Tenax Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ronald Blanck TENX stock SEC Form 4 insiders trading

Ronald has made over 5 trades of the Tenax Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of TENX stock worth $4,750 on 18 May 2020.

The largest trade he's ever made was buying 12,950 units of Tenax Therapeutics Inc stock on 18 December 2017 worth over $5,828. On average, Ronald trades about 3,867 units every 216 days since 2015. As of 18 May 2020 he still owns at least 6,062 units of Tenax Therapeutics Inc stock.

You can see the complete history of Ronald Blanck stock trades at the bottom of the page.

Ronald Blanck biography

Lieutenant General (Retired) Dr. Ronald R. Blanck, DO, USA, is Independent Chairman of the Board of Oxygen Biotherapeutics, Inc. Dr. Blanck has served as chairman of Martin, Blanck & Associates, a federal health services consulting firm based in Falls Church, VA since January 2010. He began his military career in 1968 as a medical officer and battalion surgeon in Vietnam, retiring 32 years later as a Lieutenant General and Surgeon General of the U.S. Army and commander of the U.S. Army Medical Command. He also served as commander of Walter Reed Medical Center and the North Atlantic Region Medical Command. His background also includes serving as president of the University of North Texas Health Science Center at Fort Worth.

How old is Ronald Blanck?

Ronald Blanck is 75, he's been the Independent Chairman of the Board of Tenax Therapeutics Inc since 2011. There are no older and 15 younger executives at Tenax Therapeutics Inc.

What's Ronald Blanck's mailing address?

Ronald's mailing address filed with the SEC is C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE, NC, 27560.

Insiders trading at Tenax Therapeutics Inc

Over the last 10 years, insiders at Tenax Therapeutics Inc have traded over $5,051 worth of Tenax Therapeutics Inc stock and bought 571,282 units worth $853,236 . The most active insiders traders include Capital, Llc Armistice Capi..., Declan Doogan e Stuart Rich. On average, Tenax Therapeutics Inc executives and independent directors trade stock every 218 days with the average trade being worth of $1,664,103. The most recent stock trade was executed by Gerald T Proehl on 8 August 2024, trading 1,666 units of TENX stock currently worth $6,131.

What does Tenax Therapeutics Inc do?

tenax therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions. our development portfolio includes novel product candidates that have the potential to address various critical care conditions with high unmet medical need.

Complete history of Ronald Blanck stock trades at Tenax Therapeutics Inc

Tenax Therapeutics Inc executives and stock owners

Tenax Therapeutics Inc executives and other stock owners filed with the SEC include:

• Michael B. Jebsen CPA,
  Advisor
• Anthony A. DiTonno,
  CEO & Director
• Michael Jebsen,
  President, Chief Financial Officer
• Michael B. Jebsen,
  Pres & CFO
• Christopher T. Giordano,
  CEO, Pres & Director
• Ellen Corliss,
  Vice President, Corporate Communications & Investor Relations
• Chris Rallis,
  Independent Director
• Gregory Pepin,
  Independent Director
• Gerald Proehl,
  Director
• James Mitchum,
  Director
• Keith Maher,
  Director
• Steven Boyd,
  Director
• Paula Bokesch,
  Chief Medical Officer
• Doug Randall,
  Executive Vice President - Business and Commercial Operations
• Douglas Hay,
  Executive Vice President - Regulatory Affairs
• Anthony DiTonno,
  Chief Executive Officer, Director
• Ronald Blanck,
  Independent Chairman of the Board
• Eliot M. Lurier CPA,
  Interim Chief Financial Officer
• Dr. Stuart Rich M.D.,
  Chairman of Scientific Advisory Board, Chief Medical Officer & Director
• Nancy J. M. Hecox,
  Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.
• John P Kelley,
  Chief Executive Officer
• Michael H. Davidson,
  
• Declan Doogan,
  
• Stuart Rich,
  Chief Medical Officer
• June Sherie Almenoff,
  
• Robyn Hunter,
  
• Christopher Thomas Giordano,
  CEO